Scientific breakthroughs and corporate progress.

Latest Announcements

Strategic updates, clinical pipeline milestones, and corporate developments from our Basel and Zurich facilities.

Strain V-102 Achieves 99.4% Bioactive Purity

Valgogenix Secures $18M Series A Funding

Patent Approved for Closed-Loop Carbon Capture

Our engineered microalgae strain successfully synthesized high-purity oncology compounds in closed-loop photobioreactors, matching clinical benchmarks.

Led by Horizon DeepTech Ventures, the capital will accelerate the scale-up of our industrial-grade photobioreactor facility in Basel.

The European Patent Office has granted protection for our proprietary gas-injection system, optimizing photosynthetic efficiency and carbon capture.

Technical Publications

Photosynthetic Efficiency in Closed-System Bioreactors

Metabolic Programming of Marine Microalgae

Quantifying the thermodynamic limits of carbon dioxide fixation in proprietary microalgae strains under controlled laboratory conditions.

A comprehensive analysis of carbon-negative yield optimization under sterile photobioreactor conditions, detailing molecular purity and metabolic pathway engineering.

High-Purity Extraction of Bioactive Compounds

Methodologies for solvent-free isolation of pharmaceutical-grade bioactive compounds from cellular biomass at industrial scale.

Stay informed on our scientific milestones.

Receive our quarterly technical brief and corporate updates directly from our Basel laboratory.